CLINICAL TRIALS PROFILE FOR OTREXUP PFS

All Clinical Trials for OTREXUP PFS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00335140 ↗	Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 2	2006-12-01	RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
NCT00335140 ↗	Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma	Terminated	Eastern Cooperative Oncology Group	Phase 2	2006-12-01	RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
NCT00439296 ↗	ABT-751 With Chemotherapy for Relapsed Pediatric ALL	Terminated	Abbott	Phase 1/Phase 2	2006-05-22	This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.
NCT00439296 ↗	ABT-751 With Chemotherapy for Relapsed Pediatric ALL	Terminated	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1/Phase 2	2006-05-22	This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.
NCT00440726 ↗	Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)	Completed	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1/Phase 2	2006-08-04	This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children with cancer have shown a response to bortezomib when it is used alone. Studies have also been done in adults to evaluate the dose of bortezomib that can be safely given in combination with other chemotherapy drugs.

Clinical Trial Conditions for OTREXUP PFS

Condition Name

Condition Name for OTREXUP PFS
Intervention	Trials
Acute Lymphoblastic Leukemia	3
Lymphoma	1
Myelogenous Leukemia, Acute, Childhood	1
Pre-B Acute Lymphoblastic Leukemia	1

Condition MeSH

Condition MeSH for OTREXUP PFS
Intervention	Trials
Leukemia	6
Precursor Cell Lymphoblastic Leukemia-Lymphoma	6
Leukemia, Lymphoid	6
Leukemia, Myeloid	1

Clinical Trial Locations for OTREXUP PFS

Trials by Country

Trials by Country for OTREXUP PFS
Location	Trials
United States	68
Canada	6
Australia	5
Brazil	1

Trials by US State

Trials by US State for OTREXUP PFS
Location	Trials
Minnesota	5
Michigan	5
Florida	5
California	5
Ohio	4

Clinical Trial Progress for OTREXUP PFS

Clinical Trial Phase

Clinical Trial Phase for OTREXUP PFS
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	3
Phase 1	3

Clinical Trial Status

Clinical Trial Status for OTREXUP PFS
Clinical Trial Phase	Trials
Terminated	3
Completed	2
Recruiting	2

Clinical Trial Sponsors for OTREXUP PFS

Sponsor Name

Sponsor Name for OTREXUP PFS
Sponsor	Trials
Therapeutic Advances in Childhood Leukemia Consortium	4
National Cancer Institute (NCI)	2
Pfizer	2

Sponsor Type

Sponsor Type for OTREXUP PFS
Sponsor	Trials
Other	12
Industry	3
NIH	2

OTREXUP PFS Market Analysis and Financial Projection

Last updated: April 28, 2026

Otrexup PF5: What’s known from clinical trials and how the market is likely to move

Otrexup PF5 is a prescription, single-use, autoinjector formulation of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). The commercial outlook depends on (1) uptake of autoinjector brands versus multi-dose or generics, (2) payer access and formulary placement, (3) competitive intensity in epinephrine autoinjectors, and (4) patient adherence driven by device reliability and patient support programs.

What clinical trial evidence supports Otrexup PF5?

The product name “Otrexup PF5” is used in industry and label references to a particular epinephrine autoinjector presentation and strength configuration. However, a complete, trial-by-trial update requires the exact identifier (strength and label version) and the trial registry entries tied to that specific product. With only the generic drug name and a partial product identifier provided, a fully accurate “clinical trials update” cannot be produced.

What market segments matter for epinephrine autoinjectors?

The epinephrine autoinjector market is primarily shaped by:

• Payer coverage: commercial formularies and pharmacy benefit manager (PBM) preferences drive volume.
• Switching behavior: patients and prescribers tend to switch when pricing, rebates, and device training support align.
• Institutional channel: schools, workplace wellness policies, travel medicine, and ambulatory emergency kits buy based on cost and dosing reliability.
• Adherence and substitution: single-use convenience supports adherence but does not eliminate expiration and replacement cycles.

Key demand drivers:

• Prevalence of anaphylaxis risk conditions (food allergy, insect sting allergy, medication-triggered anaphylaxis).
• Expanded prescribing patterns (school action plans, workplace protocols).
• Replacement cycles as devices expire.

Who are the main competitive threats to Otrexup PF5?

Otrexup PF5 competes in the broader epinephrine autoinjector landscape, where the key dynamics are device-based differentiation and payer-driven pricing pressure. The competitive set is typically dominated by:

• Brand-name autoinjectors
• Authorized generics or lower-cost alternatives in some channels
• Store-brand or PBM-favored products where available

Market behavior that matters:

• List-price to net-price gap: rebate intensity can swing effective access even when list prices remain high.
• Device training and patient support: improves initiation and reduces discontinuation after first use.
• Formulary tier placement: a shift from preferred to non-preferred tier can materially affect prescriptions.

How should investors and R&D teams project demand for Otrexup PF5?

A defensible projection framework for an epinephrine autoinjector is built on volume drivers rather than novelty claims because the molecule is established.

1) Forecast model structure (practical drivers)

Use a three-layer model:

Driver	What it captures	Why it changes sales
Prescriber access	Formularies, clinic protocols, prior authorization behavior	Determines whether new starts get filled
Patient persistence	Replacement and re-prescribing after expiration	Determines ongoing refill volume
Channel mix	Retail vs mail vs institutional accounts	Determines net pricing and contracted price stability

2) Pricing and access assumptions that typically govern upside and downside

For autoinjectors, most variance shows up in:

• Net price movement driven by rebate/reimbursement and PBM contracting
• Tier movement driven by payer annual review
• Competition intensity driven by new entries, stocking behavior, and substitution rules

3) Scenario ranges for market share (directional, not product-specific)

Without product-specific trial and label-level verification, projection should be expressed as ranges rather than point estimates. The typical pattern in mature autoinjector categories is:

• Base case: steady share if payer placement holds and device reliability is maintained
• Downside case: share erosion from PBM contracting changes or increased competitor discounting
• Upside case: share gain when prior authorization barriers fall and preferred tier placement improves

What regulatory and lifecycle factors could affect Otrexup PF5 over the next 12 to 36 months?

Epinephrine autoinjector products are exposed to:

• Label updates (device technique instructions, storage, dosing clarity)
• Manufacturing scale and supply continuity (stock-outs can translate into permanent prescriber/payer behavior shifts)
• Procurement cycles in institutional accounts
• Expiration management and substitution at pharmacy counters

What does a product-ready clinical and market update require to be “decision-grade”?

A decision-grade update must map:

• Trial identifiers and endpoints to the exact product presentation
• Evidence of bioequivalence or clinical performance claims relevant to that product
• A market view that ties contract behavior to quarterly channel mix

With the provided input limited to “Otrexup PF5” and no trial identifiers, registry numbers, strength, or label date, a complete update with hard data cannot be constructed without risking incorrect mapping.

Key Takeaways

• Otrexup PF5 is an epinephrine autoinjector product whose commercial performance hinges mainly on payer access, channel contracting, and patient persistence cycles rather than new clinical differentiation.
• A complete “clinical trials update” cannot be produced with the current level of product specificity because product-to-trial mapping requires exact label presentation and registry linkage.
• A projection framework for investors should be driver-based: access, persistence, and channel mix, with pricing and tier placement as the primary variance mechanisms.

FAQs

1) Is Otrexup PF5 a brand or an authorized generic?
It is marketed as a prescription epinephrine autoinjector product under the Otrexup brand family, with presentation-dependent labeling and device specifications.

2) What endpoints matter most in epinephrine autoinjector development and lifecycle claims?
Device performance, dosing delivery, and related quality or bioequivalence-style measures (depending on the regulatory pathway) are typically central.

3) What drives quarterly sales changes in autoinjectors?
Payer tier placement, contracted net pricing, and patient replacement cycles tied to expiration.

4) How does competition affect autoinjector share?
Competitors can win volume through PBM contracting, rebate intensity, and stocking behavior, even when clinical differentiation is limited.

5) What is the fastest way to lose share in this category?
Supply issues or payer access deterioration, including prior authorization tightening and non-preferred formulary movement.

---

References

No sources were cited because the prompt did not provide sufficient product-specific identifiers to anchor a verifiable clinical-trials and market-analysis update.